# Apyx Medical Corporation to Participate in Upcoming November Investor Conferences
Canonical URL: https://biopharmsignal.com/news/APYX/apyx-medical-corporation-to-participate-in-upcoming-november-investor-conference-66d31e56
Ticker: APYX
Company: Apyx Medical
Source: Apyx Medical
Published: 2025-10-27 12:00 EST
## Summary

Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a...

## Article Body
Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion ® and the AYON Body Contouring System™, today announced that Charles Goodwin, President and CEO and Matt Hill, CFO will be attending the following upcoming conferences:

Event: 16th Annual Craig-Hallum Alpha Select Conference Date: Tuesday, November 18, 2025 Location: Sheraton NY Times Square Hotel, New York, NY Format: 1x1 Meetings

Event: Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum Date: Thursday, November 20, 2025 Location: Westin NY Grand Central, New York, NY Format: 1x1 Meetings

To request a meeting with Apyx, investors should contact their Craig Hallum and Canaccord Genuity representatives.

About Apyx Medical Corporation :

Apyx Medical Corporation is an advanced energy technology company with a passion for elevating people’s lives through innovative products, including its Helium Plasma Platform Technology products marketed and sold as Renuvion ® and the AYON Body Contouring System™ in the cosmetic surgery market and J-Plasma ® in the hospital surgical market. Renuvion and J-Plasma offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The effectiveness of Renuvion and J-Plasma are supported by more than 90 clinical documents. The AYON Body Contouring System™ is an FDA-cleared, groundbreaking, surgeon-designed body contouring system that combines precision, versatility, and innovation in an all-in-one platform. It seamlessly integrates fat removal, closed loop contouring, tissue contraction, and electrosurgical capabilities, empowering surgeons to deliver the most comprehensive body contouring treatments for patients. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. For further information about the Company and its products, please refer to the Apyx Medical Corporation website at www.ApyxMedical.com

Investor Relations Contact : Jeremy Feffer Managing Director LifeSci Advisors OP: 212-915-2568 jfeffer@lifesciadvisors.com
## Recent Company News
- 2026-07-28 12:00 EST — [Apyx Medical Corporation to Participate in the Canaccord Genuity 46th Annual Growth Conference](https://biopharmsignal.com/news/APYX/apyx-medical-corporation-to-participate-in-the-canaccord-genuity-46th-annual-gro-94590452) — Source: Apyx Medical
- 2026-07-23 12:00 EST — [Apyx Medical Corporation to Release Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026](https://biopharmsignal.com/news/APYX/apyx-medical-corporation-to-release-second-quarter-of-fiscal-year-2026-financial-0275b558) — Source: Apyx Medical
- 2026-05-21 12:00 EST — [New Study Shows Significant Improvement in Cellulite and Skin Laxity with Advanced Minimally Invasive Treatment Utilizing Avéli® and Renuvion®](https://biopharmsignal.com/news/APYX/new-study-shows-significant-improvement-in-cellulite-and-skin-laxity-with-advanc-d19ed0bc) — Source: Apyx Medical
- 2026-05-14 12:00 EST — [Apyx Medical Corporation Announces Retrospective Clinical Publication Evaluating Clinical Benefit of Renuvion® Used in Combination with Liposuction](https://biopharmsignal.com/news/APYX/apyx-medical-corporation-announces-retrospective-clinical-publication-evaluating-065196d3) — Source: Apyx Medical
- 2026-05-11 12:00 EST — [Apyx Medical Corporation Receives Expanded FDA 510(k) Clearance Adding Power Liposuction Capability to AYON Body Contouring System™](https://biopharmsignal.com/news/APYX/apyx-medical-corporation-receives-expanded-fda-510-k-clearance-adding-power-lipo-c64ec7c1) — Source: Apyx Medical
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)